Merck Serono Unveils New Eeva Test

Merck Serono, a Merck subsidiary, has launched its next-generation Eeva test, an embryo assessment aid for assisted reproductive treatment.

The product features a new algorithm, Xtend, that models, assesses and predicts embryonic development, the German devicemaker said. When combined with morphology, it increases the odds of detecting embryos with the highest developmental potential.

The new Eeva test will be available in Europe and Canada by the end of the first half of this year. In the U.S., the system was FDA de novo cleared in 2014.

Progyny, which developed the test, granted Merck Serono exclusive commercialization rights. — Jason Scott